MX2020007429A - Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). - Google Patents

Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).

Info

Publication number
MX2020007429A
MX2020007429A MX2020007429A MX2020007429A MX2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A
Authority
MX
Mexico
Prior art keywords
antibodies
subcutaneous dosing
disclosed
methods
diseases
Prior art date
Application number
MX2020007429A
Other languages
English (en)
Inventor
Robert Evans
Martin Dahl
Eric Fedyk
Lin Zhao
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020007429A publication Critical patent/MX2020007429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para administrar anticuerpos anti-CD38 aislados a dosis bajas por vía subcutánea. Los métodos proporcionan un tratamiento eficaz para enfermedades autoinmunitarias y tipos de cáncer, incluso enfermedades hematológicas. También se describen formas de dosis unitaria para los anticuerpos anti-CD38.
MX2020007429A 2018-01-12 2019-01-14 Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). MX2020007429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862617146P 2018-01-12 2018-01-12
PCT/US2019/013547 WO2019140410A1 (en) 2018-01-12 2019-01-14 Subcutaneous dosing of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
MX2020007429A true MX2020007429A (es) 2020-10-15

Family

ID=65529766

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007429A MX2020007429A (es) 2018-01-12 2019-01-14 Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
MX2026000035A MX2026000035A (es) 2018-01-12 2020-07-13 Formas de dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38) para uso farmaceutico en el tratamiento de una enfermedad caracterizada por la expresion de cd38

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2026000035A MX2026000035A (es) 2018-01-12 2020-07-13 Formas de dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38) para uso farmaceutico en el tratamiento de una enfermedad caracterizada por la expresion de cd38

Country Status (11)

Country Link
US (2) US12371506B2 (es)
EP (1) EP3737702B1 (es)
JP (2) JP7812612B2 (es)
KR (1) KR20210006321A (es)
CN (1) CN112739715A (es)
AU (1) AU2019208102B2 (es)
BR (1) BR112020014052A2 (es)
CA (1) CA3088199A1 (es)
CO (1) CO2020008561A2 (es)
MX (2) MX2020007429A (es)
WO (1) WO2019140410A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
US12181485B2 (en) * 2020-09-10 2024-12-31 CASI Pharmaceuticals, Inc Methods of blood screening
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20250135226A (ko) 2023-01-06 2025-09-12 다케다 야쿠힌 고교 가부시키가이샤 자가면역 질환의 치료를 위한 항-cd38 항체
KR20250052963A (ko) 2023-10-12 2025-04-21 주식회사 쿠노소프트 글로벌 지능형 b2b 기업매칭 시스템
WO2025160986A1 (en) * 2024-02-02 2025-08-07 Keymed Biosciences (Chengdu) Co., Ltd. An anti-cd38 monoclonal antibody and application thereof
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
WO2025213286A1 (zh) * 2024-04-07 2025-10-16 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
EP2328615A2 (en) 2008-08-20 2011-06-08 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
GB2486424A (en) 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
GB201203938D0 (en) 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
GB201212900D0 (en) 2012-07-20 2012-09-05 Binding Site Group The Ltd Triage scoring system
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
SG11201600666SA (en) 2013-07-30 2016-02-26 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
CN120501855A (zh) 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Also Published As

Publication number Publication date
BR112020014052A2 (pt) 2020-12-08
JP7812612B2 (ja) 2026-02-10
US20210388103A1 (en) 2021-12-16
JP2024023247A (ja) 2024-02-21
EP3737702A1 (en) 2020-11-18
EP3737702B1 (en) 2026-07-29
RU2020126723A3 (es) 2022-02-14
US20260103534A1 (en) 2026-04-16
CN112739715A (zh) 2021-04-30
KR20210006321A (ko) 2021-01-18
JP2021510737A (ja) 2021-04-30
WO2019140410A1 (en) 2019-07-18
US12371506B2 (en) 2025-07-29
AU2019208102A1 (en) 2020-07-02
CO2020008561A2 (es) 2020-10-30
MX2026000035A (es) 2026-06-01
RU2020126723A (ru) 2022-02-14
CA3088199A1 (en) 2019-07-18
AU2019208102B2 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
CO2020008561A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2019012462A (es) Terapia combinada.
MY189536A (en) Subcutaneous her2 antibody formulations
MX2022003930A (es) Conjugados de péptido de camptotecina.
WO2020081881A3 (en) Method of providing subcutaneous administration of anti-cd38 antibodies
MX2021002764A (es) Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
JOP20220071A1 (ar) سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
ZA202202363B (en) Antibodies against ilt2 and use thereof
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
TN2018000021A1 (en) ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2019006131A (es) Metodos para tratar cancer de mama positivo para prlr.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2020001727A (es) Terapia de combinacion.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
MY206426A (en) Anti-cd38 antibodies and formulations